This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe

ONLINE REGISTRATION CLOSES IN:

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event, 7 - 9 June, 2022
Live In-Person Event: 7 - 9 June, Postillion Hotel AmsterdamDigital Experience: All Sessions Livestreamed 7 - 9 June

Absolute Antibody

Profile

Absolute Antibody specializes in antibody sequencing, engineering and recombinant expression, offering royalty-free services and a catalog of engineered recombinant antibodies. We sequence from hybridomas or purified protein, rapidly reformat antibodies, and produce recombinant antibodies at milligram-to-gram scale. Our proprietary platform enables antibody engineering such as humanization, chimerization, species switching, isotype or subtype switching, creating antibody fragments, and developing custom bispecific or trispecific antibodies.

 

Our team has deep expertise in therapeutic antibody development, and we partner with leading pharmaceutical and biotechnology companies around the world to produce antibodies in a wide range of formats. Since our founding in 2012, we have made more than 140 different antibody formats for our customers, which include 14 of the top 15 pharmaceutical companies by revenue. Depending on your needs, we can provide a reliable outsourcing solution for antibody sequencing, engineering and expression, or a true consultative partnership for developing the best possible antibody candidate.